SLC39A14 Protein
Overview
SLC39A14, commonly known as ZIP14 (Zinc Transporter 14), is a metal ion transporter belonging to the solute carrier family 39 (SLC39A). This protein functions as a bidirectional transporter of zinc and other divalent metal cations, including cadmium, manganese, and iron. SLC39A14 is encoded by the SLC39A14 gene located on chromosome 8q24.3 in humans. The protein is characterized by eight transmembrane domains and represents one of the most versatile metal transporters in the ZIP family, with expression in multiple tissues including liver, kidney, pancreas, and importantly, the brain. The physiological importance of SLC39A14 has become increasingly apparent through the discovery of mutations causing a specific form of neurodegeneration.
Function/Biology
SLC39A14 operates as a zinc influx transporter, facilitating the movement of zinc from the extracellular space or intracellular compartments across cell membranes. Beyond zinc, the protein exhibits broad metal substrate specificity, transporting cadmium, manganese, and potentially other transition metals with varying affinities. The transporter utilizes electrochemical gradients to drive metal ion movement and is regulated by zinc availability, with feedback mechanisms controlling expression levels under different metal saturation states.
...SLC39A14 Protein
Overview
SLC39A14, commonly known as ZIP14 (Zinc Transporter 14), is a metal ion transporter belonging to the solute carrier family 39 (SLC39A). This protein functions as a bidirectional transporter of zinc and other divalent metal cations, including cadmium, manganese, and iron. SLC39A14 is encoded by the SLC39A14 gene located on chromosome 8q24.3 in humans. The protein is characterized by eight transmembrane domains and represents one of the most versatile metal transporters in the ZIP family, with expression in multiple tissues including liver, kidney, pancreas, and importantly, the brain. The physiological importance of SLC39A14 has become increasingly apparent through the discovery of mutations causing a specific form of neurodegeneration.
Function/Biology
SLC39A14 operates as a zinc influx transporter, facilitating the movement of zinc from the extracellular space or intracellular compartments across cell membranes. Beyond zinc, the protein exhibits broad metal substrate specificity, transporting cadmium, manganese, and potentially other transition metals with varying affinities. The transporter utilizes electrochemical gradients to drive metal ion movement and is regulated by zinc availability, with feedback mechanisms controlling expression levels under different metal saturation states.
In systemic physiology, SLC39A14 contributes to whole-body zinc homeostasis and plays a crucial role in regulating manganese accumulation in tissues. The protein is particularly important in the liver, where it participates in hepatic zinc metabolism and detoxification pathways. In pancreatic β-cells, SLC39A14 helps maintain zinc stores essential for insulin synthesis, processing, and secretion. At the cellular level, the transporter localizes to the plasma membrane, endosomes, and potentially vesicular compartments, allowing it to coordinate both extracellular zinc acquisition and intracellular metal trafficking.
Role in Neurodegeneration
Mutations in SLC39A14 cause hypermanganesemia with dystonia 2 (HMNDYT2), a rare autosomal recessive neurological disorder characterized by progressive movement disturbances, cognitive decline, and selective manganese accumulation in the basal ganglia and other brain regions. Affected individuals typically present with dystonia, parkinsonism, spasticity, and psychiatric manifestations. Neuroimaging reveals characteristic T1-weighted hyperintensities in the globus pallidus, putamen, and substantia nigra—regions critical for motor control—reflecting pathological manganese deposition.
Loss-of-function mutations impair SLC39A14's ability to transport manganese, paradoxically leading to manganese accumulation in the brain while causing manganese depletion systemically. This apparent contradiction occurs because impaired SLC39A14 function disrupts the normal excretion pathways for manganese, causing secondary manganese accumulation in the central nervous system through alternative, less efficient transport mechanisms. The progressive nature of the disease suggests that chronic manganese accumulation triggers neuronal dysfunction and neurodegeneration through oxidative stress and mitochondrial dysfunction.
Molecular Mechanisms
The pathogenic mechanism in HMNDYT2 involves disrupted metal homeostasis. SLC39A14 normally participates in manganese efflux from the brain or reduces manganese influx through the blood-brain barrier. When SLC39A14 function is compromised, manganese accumulates preferentially in mitochondria-rich regions of neurons, particularly in the basal ganglia. Excess manganese generates reactive oxygen species (ROS) through Fenton-like reactions, overwhelming endogenous antioxidant defenses including superoxide dismutase (SOD) and catalase. This oxidative stress damages mitochondrial membranes, impairs ATP production, and triggers excitotoxic cascades, ultimately leading to selective neuronal death in motor control circuits.
Clinical/Research Significance
SLC39A14 mutations represent the primary genetic cause of hereditary manganese accumulation disorders. Recognition of this pathway has clinical implications for diagnosis and potential therapeutic interventions. Chelation therapy targeting manganese accumulation shows promise in some cases, particularly when initiated early. Research continues investigating pharmacological SLC39A14 activators or alternative approaches to enhance manganese clearance from the brain. The study of SLC39A14 has also illuminated broader principles of how metal transporter dysfunction causes selective neurodegeneration and the critical role of metal homeostasis in neurodegenerative disease etiology.
- ZIP family transporters (SLC39A1, SLC39A8, SLC39A10)
- Manganese metabolism and toxicity
- Basal ganglia disorders
- Dystonia and parkinsonism syndromes
- Mitochondrial dysfunction in neurodegeneration
- Oxidative stress pathways